glp-1 neuroendocrine tumor GLP-1R agonist promotes proliferation of neoplasm cells expressing receptors Representative images with Ki-67-labeling index

Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference

If the hindlimbs stretched outward constantly without any abnormal movement, a score of 0 was assigned

Maintaining data integrity and traceability is also critical

High-Protein, GLP-1 Friendly Nutrition Discover your favorite flavor with the Biocare 30G Protein Beverage Variety Pack

doi: 10.1080/00325481.2021.1971461